Clinical Trials List
2024-09-01 - 2028-03-01
Phase II
Not yet recruiting1
Recruiting2
ICD-10C95.00
Acute leukemia of unspecified cell type not having achieved remission
ICD-10C95.02
Acute leukemia of unspecified cell type, in relapse
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9208.00
Acute leukemia of unspecified cell type, without mention of remission
-
Trial Applicant
Johnson & Johnson
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- Ya-Ting Hsu Division of Hematology & Oncology
- Sin-Syue Li Division of Hematology & Oncology
- 傅蓓安 Division of Hematology & Oncology
- Ya-Ping Chen Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 李思慧 Division of Hematology & Oncology
- Huai-Hsuan Huang Division of Hematology & Oncology
- 田豐銘 Division of General Internal Medicine
- Chien-Chin Lin Division of Others -
- - - Division of Hematology & Oncology
- 林明恩 Division of General Internal Medicine
- YAO CHI-YUAN Division of General Internal Medicine
- Chieh-Lung Cheng Division of General Internal Medicine
- Wen-Chien Chou Division of Hematology & Oncology
- MING YAO Division of Hematology & Oncology
- CHENG-HONG TSAI Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- 王幸婷 Division of Hematology & Oncology
- 陳珈妤 Division of Hematology & Oncology
- 王秀慈 Division of Hematology & Oncology
- Chi-Ching Chen Division of Hematology & Oncology
- 鄭富銘 Division of Hematology & Oncology
- Ming-Yu Lien Division of Hematology & Oncology
- Yu-Min Liao Division of Hematology & Oncology
- Che-Hung Lin Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
15 participants
-
Global
200 participants
